Shares of Evotec AG (NASDAQ:EVO – Get Free Report) crossed below its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $1.60 and traded as low as $1.57. Evotec shares last traded at $1.58, with a volume of 46,513 shares.
Analyst Upgrades and Downgrades
A number of research firms have weighed in on EVO. Weiss Ratings downgraded shares of Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 25th. HC Wainwright increased their price objective on shares of Evotec from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Friday, November 6th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $3.50.
Get Our Latest Stock Analysis on Evotec
Evotec Price Performance
The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.19 and a current ratio of 2.32. The firm has a 50 day simple moving average of $1.60 and a 200-day simple moving average of $2.43.
Institutional Investors Weigh In On Evotec
An institutional investor recently raised its position in Evotec stock. Optiver Holding B.V. boosted its position in shares of Evotec AG (NASDAQ:EVO – Free Report) by 598.4% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 283,576 shares of the company’s stock after purchasing an additional 242,973 shares during the period. Optiver Holding B.V. owned about 0.08% of Evotec worth $709,000 at the end of the most recent quarter. Institutional investors and hedge funds own 5.81% of the company’s stock.
Evotec Company Profile
Evotec SE is a life sciences company headquartered in Hamburg, Germany, that provides drug discovery and development services to pharmaceutical, biotechnology and academic partners. Its work spans early-stage research through preclinical and clinical development, using expertise in areas such as biology, chemistry and data-driven drug discovery. The company supports programs across multiple therapeutic areas and develops both small-molecule and biologic medicines. Its Just-Evotec Biologics business focuses on the development and production of biologics, including services intended to help partners advance treatments from research toward clinical and commercial use.
Further Reading
- Five stocks we like better than Evotec
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.
